United States · Investor

Balyasny Asset Management L.p.

Last cheque observed Oct 2026; 7 cheques on record.

Deploying nowPrivate equity

SeedSeries ASeries BFinTechFood And Beverage

Deploying now
100%of best year3cheques in 12 months, 7 on record
Since the last cheque4days00hrs00min00sec
Median round$238MRounds led0 of 7Exits1 from the portfolioMostly inUnited States, 86%
Pitch Balyasny Asset Management L.p.

Balyasny Asset Management L.p. highlights

  1. 01

    3 cheques in the last 12 months

  2. 02

    Mostly Series C and Series B: 67% of its rounds

  3. 03

    1 exits from the portfolio

What they do

Type
Private equity (from a list, unverified)
Cheque size
Up to $5.0M as they say
Stages
SeedSeries ASeries BGrowth
Sectors
FinTechFood And Beverage
Based in
Chicago, United States
Cold pitches
Not stated

The record

Every round we can evidence, newest first7 appearances

  1. 2026

    2 rounds

  2. Oct
    Zai LabCN · Pulse 2.0$250MWith 10 others
  3. Oct
    Soufflé TherapeuticsSeries B · US · Google News search$135MWith 16 others
  4. 2025

    2 rounds

  5. Nov
    Aspen NeuroscienceSeries C · US · Ventureburn$115MWith 9 others
  6. May
    ForterraSeries C · US · Crescent Cove$238MWith 11 others
  7. 2021

    1 round

  8. Jul
    Nature's FyndSeries C · US · Firms' own news pages$350MWith 6 others
  9. 2015

    1 round

  10. Sept
    AvantSeries E · US$325MWith 6 others
  11. 2005

    1 round

  12. Jul
    PharmacopeiaVenture · US$7.6MWith 9 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

The team

We hold 37 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

Exits from the portfolio

Companies it backed that were later bought or listed1 in all

PharmacopeiaBought by Ligand Pharmaceuticals$73MSept 2008

An exit counts when it came after the firm's first round in the company. From historical deal records.

Who they invest alongside

The investors most often in the same rounds as Balyasny Asset Management L.p.. A count of rooms they were both in, not a relationship either has claimed.

Recently backed

The latest companies Balyasny Asset Management L.p. put money into.

Quick answers about Balyasny Asset Management L.p.

What does Balyasny Asset Management L.p. invest in?

Balyasny Asset Management L.p. invests most often at Series C and Series B (67% of the rounds on record), in sectors such as FinTech and Food And Beverage.

How active is Balyasny Asset Management L.p.?

7 investments on record, 3 of them in the last 12 months. The most recent was in Oct 2026.

What has Balyasny Asset Management L.p. invested in recently?

Its most recent investments on record: Zai Lab (Undisclosed round, Oct 2026), Soufflé Therapeutics (Series B, Oct 2026) and Aspen Neuroscience (Series C, Nov 2025).

How big are Balyasny Asset Management L.p.'s cheques?

The median round it joins is $238M.

Does Balyasny Asset Management L.p. lead rounds?

Rarely, if at all: none of its 7 investments on record names it as the lead.

Where does Balyasny Asset Management L.p. invest?

Most of the companies it backs are in the United States (86%) and China (14%).

Is Balyasny Asset Management L.p. investing now?

Yes: it is actively investing, with 3 investments in the last 12 months.

Who does Balyasny Asset Management L.p. invest alongside?

Most often ARCH Venture Partners (2 rounds together), Cormorant Asset Management (2 rounds together) and Frazier Life Sciences (2 rounds together).

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it